Ra Pharma (RARX) PT Raised to $34 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria
December 4, 2017 7:00 AM EST
- Dosing Complete, Primary Endpoint Met in Eculizumab Naïve Cohort
(p=0.002 for LDH reduction)
- Switch Cohort: Interim Data
Demonstrate Successful Switching from Eculizumab
- Phase 2
Enrollment Complete in All Cohorts
- Company to Host
Conference Call Today, December 4, at 8:00am ET to Discuss Interim Data
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:... More
